Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Syensqo SA/NV (SYENS.BR)
Brussels, BE
Syensqo SA/NV operates as a global scientific enterprise, conducting its business through two primary divisions: Materials, and Consumer & Resources. The company supplies an extensive portfolio of chemical products, including various amines, antioxidants, stabilizers, and advanced composites. Its offerings further encompass flavors and fragrances, such as different forms of vanillin and cyclopentanone, alongside lithium-based compounds like salts and cryolite, diphenols, hydrocarbon monomers, and specialized phosphorus derivatives. Additionally, Syensqo develops a broad spectrum of polymers, ranging from biobased and synthetic to high-performance and specialty variants, including aromatic polyamides, fluoropolymers, and polyolefins. The company also provides solvents (featuring green alternatives), flame retardants, other specialty chemicals, and a comprehensive range of surfactants (amphoteric, anionic, cationic, non-ionic, and blended types). These sophisticated materials and solutions are utilized across a multitude of sectors, such as transportation, aerospace, automotive, building, chemical, consumer goods, electronics, energy, food, healthcare, home and personal care, industrial, agriculture, mining, and oil and gas. Established in 1863, Syensqo SA/NV maintains its headquarters in Brussels, Belgium.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.59% | +8.40% | +9.45% | -21.90% | -8.28% | -9.64% | -2.59% | -37.38% | -37.38% | -37.38% | -37.38% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 7 | 0 |
| Hold | 8 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals: +4.0%-15.8% Q1'26: -16.6% (vs Q1'25)
-
EPS growth Chemicals: +11.7%-1,157.9% Q1'26: +2,161.9% (vs Q1'25)
-
FCF margin FCF growth · Chemicals: +41.7%+3.8% Q1'26: +7.7% (vs Q1'25)
-
EBIT margin Chemicals: +7.1%+7.4% ★ Q1'26: +4.6% (vs Q1'25)
-
ROIC Chemicals: +3.4%+3.1%
-
Share dilution Chemicals: +0.0%-1.4% ★ Q1'26: -0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×2.64× Q1'26: 11.57× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 17 Rev. Ana. 6 EPS Ana. |
Dec 2027 17 Rev. Ana. 13 EPS Ana. |
Dec 2028 12 Rev. Ana. 4 EPS Ana. |
Dec 2029 11 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
7.07B
est: 6.92B (+2.1%)
|
6.85B
est: 6.61B (+3.6%)
|
5.76B
est: 6.29B (-8.5%)
|
5.80B
5.47B – 6.72B
-7.9% YoY
|
6.06B
5.72B – 6.93B
+4.5% YoY
|
6.30B
6.28B – 6.31B
+3.9% YoY
|
6.44B
6.09B – 7.42B
+2.4% YoY
|
| EBITDA |
1.17B
est: 955.45M (+22.8%)
|
1.22B
est: 1.25B (-2.6%)
|
1.12B
est: 1.19B (-5.7%)
|
1.09B
1.03B – 1.27B
-7.9% YoY
|
1.14B
1.08B – 1.31B
+4.5% YoY
|
1.19B
1.19B – 1.19B
+3.9% YoY
|
1.22B
1.15B – 1.40B
+2.4% YoY
|
| EBIT |
554.00M
est: 281.63M (+96.7%)
|
483.00M
est: 602.28M (-19.8%)
|
426.00M
est: 573.62M (-25.7%)
|
528.19M
498.70M – 612.66M
-7.9% YoY
|
552.19M
521.60M – 631.85M
+4.5% YoY
|
573.76M
572.24M – 575.27M
+3.9% YoY
|
587.27M
554.62M – 676.49M
+2.4% YoY
|
| Net Income |
193.00M
est: 760.52M (-74.6%)
|
-5.00M
est: 626.35M (-100.8%)
|
-62.00M
est: 474.20M (-113.1%)
|
367.81M
256.57M – 479.05M
-22.4% YoY
|
447.29M
277.48M – 617.10M
+21.6% YoY
|
466.01M
397.88M – 534.15M
+4.2% YoY
|
616.90M
572.30M – 738.73M
+32.4% YoY
|
| SGA |
817.00M
est: 848.42M (-3.7%)
|
1.01B
est: 841.24M (+19.5%)
|
883.00M
est: 801.20M (+10.2%)
|
737.76M
696.57M – 855.74M
-7.9% YoY
|
771.28M
728.55M – 882.53M
+4.5% YoY
|
801.40M
799.28M – 803.52M
+3.9% YoY
|
820.28M
774.66M – 944.89M
+2.4% YoY
|
| EPS |
1.82
est: 7.26 (-74.9%)
|
-0.05
est: 5.70 (-100.8%)
|
-0.60
est: 4.32 (-113.9%)
|
3.24
2.48 – 4.64
-25.0% YoY
|
3.90
2.69 – 5.97
+20.5% YoY
|
4.41
3.85 – 5.17
+13.2% YoY
|
5.97
5.54 – 7.15
+35.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-15 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| J. Michael Radossich | Chief Executive Officer & Director | 8M | male |
| Christopher Roger Davis | Chief Financial Officer | 2M | male |
| Kerstin Artenberg | Chief People Officer | 850.0K | female |
| Brian S. Belanger | General Counsel | 763.3K | male |
| Sherief Hassan Bakr | Head of Investor Relations | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SYENS.BR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
